Inve India ▾

FDC share price & results

FDC Limited· Healthcare

Results to
Jun 2026
Ownership as of
Sept 2026

Mumbai pharma maker of branded generics (Electral, Zifi, Enerzal), APIs, sold across 50+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue668 ₹ crore+3.1% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin21.0 %−1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit132 ₹ crore+9.1% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity12.84 %−0.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin1.84 %−8.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)3.45 %−5.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Price

₹346.45 +2.29% · +₹7.75

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −19.5% 1Y

₹350₹400₹450Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹430.25 on 24 Oct 2025 → ₹346.45. High ₹460.65 (31 Oct 2025), low ₹321.1 (27 Mar 2026).

Previous close
₹338.7
Market cap
₹5.8k Cr
52-week range
₹321.1 – ₹460.65
One year
−19.74%
Price to earnings (TTM to Jun 2026)
18.86×
Return on equity (TTM to Jun 2026)
12.84%

Overview

Symbol
NSE:FDC
Exchange
NSE
Currency
INR

What FDC Limited does

Based on the company's own presentations, annual report and earnings calls.

FDC Limited is an India-based pharmaceutical company that develops, manufactures and markets branded generic formulations, active pharmaceutical ingredients (APIs) and nutraceuticals. Its domestic portfolio spans anti-infectives, gastrointestinal, ophthalmic, cardiovascular, anti-diabetic, dermatology, paediatric and vitamin/mineral/nutraceutical therapy areas, sold through its own field force to doctors and pharmacies. It also manufactures APIs in-house to backward-integrate its formulation business, and exports formulations and APIs to markets across Europe, Africa, the Middle East and Asia-Pacific, with a separate US-focused generics filing pipeline.

Segments

  • Domestic Formulations
  • Export/International Formulations
  • API
Manufacturing facilities
7 plants across India (6 formulation + 1 API)
Manufacturing locations
Roha (API), Waluj, Goa I, Goa II, Goa III, Sinnar, Baddi
Countries served
50+ countries across Europe, Africa, APAC and the Middle East
Products registered internationally
401 products registered across 51 countries
Domestic field force
~4,800-strong field force calling on doctors
In-house R&D centres
2 (Jogeshwari and Kandivali, Mumbai)
Founded 1936Headquarters Mumbai, Maharashtra, IndiaEmployees 6,000 (2023-09-30) Company website

Your own record

Start an Inve Case for FDC Limited

Free account: one company. Everything above stays public.

Write why you follow FDC Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse FDC Limited

Guides on how to read this kind of business and the numbers that matter.